Skip to Content
Merck
All Photos(2)

Documents

917478

Sigma-Aldrich

BocA1V1PF2

≥95%

Synonym(s):

(S)-2-((S)-1-((S)-2-((S)-2-((tert-Butoxycarbonyl)amino)propanamido)-3,3-dimethylbutanoyl)pyrrolidine-2-carboxamido)-3-(4-fluorophenyl)propanoic acid, AVP ligand, IAP E3 ligase lead for protein degrader research, SNIPER building block

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C28H41FN4O7
Molecular Weight:
564.65
UNSPSC Code:
41116105
NACRES:
NA.22

ligand

BocA1V1PF2

Quality Level

100

Assay

≥95%

form

powder

reaction suitability

reagent type: ligand

functional group

carboxylic acid

storage temp.

2-8°C

SMILES string

C[C@H](NC(OC(C)(C)C)=O)C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(O)=O)CC2=CC=C(C=C2)F)=O)=O)C(C)(C)C)=O

Related Categories

Application

BocA1V1PF2 is an in silico-derived inhibitor of apoptosis protein (IAP)-recruiting ligand for targeted protein degradation and SNIPER (specific and non-genetic IAP-dependent protein erasers) development, launched in partnership with ComInnex. Learn more about the novel IAP ligands generated through virtual screening of AVP mimetics in our Technology Spotlight. A C-terminal variant of BocA1V1PF2 is also available as A1V1PF2-OEt (917710).

BocA1V1PF2 conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining SNIPER and PROTAC® degrader libraries: Degrader Building Blocks
916927 BocA1V1PF2-OC6-NH2 hydrochloride
917184 BocA1V1PF2-OC10-NH2 hydrochloride
917435 BocA1V1PF2-OPEG1-NH2 hydrochloride
917680 BocA1V1PF2-OPEG3-NH2 hydrochloride

Technology Spotlight: Degrader Building Blocks with Inhibitor of Apoptosis Protein (IAP) In Silico-Derived Ligands

Other Notes

In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)

SNIPERs−Hijacking IAP activity to induce protein degradation

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

related product

Product No.
Description
Pricing

917931

A1V2PF2-NHEt-C6-NH2

916684

A1V2PF2-NHEt-C10-NH2, ≥95%

917680

BocA1V1PF2-OPEG3-NH2 hydrochloride

917966

BocA1V2PF1-NHC6-NH2

917702

A1V2PF1-NHEt-PEG3-NH2

917451

A1V2PF1-NHEt-PEG1-NH2, ≥95%

917974

BocA1V2PF2

917710

A1V1PF2-OEt, ≥95%

917214

BocA1V2PF1-NHPEG3-NH2, ≥85%

916951

BocA1V2PF1-NHPEG1-NH2

916927

BocA1V1PF2-OC6-NH2 hydrochloride, ≥95%

916676

A1V1PF2-OEt-PEG3-NH2 hydrochloride

917923

A1V1PF2-OEt-PEG1-NH2 hydrochloride

917672

A1V1PF2-OEt-C10-NH2 hydrochloride

917206

A1V2PF1-NHEt-C10-NH2

917184

BocA1V1PF2-OC10-NH2 hydrochloride

916943

A1V2PF1-NHEt-C6-NH2

916692

BocA1V2PF2-NHPEG3-NH2, ≥95%

917427

A1V1PF2-OEt-C6-NH2 hydrochloride

916706

BocA1V2PF1-NHC10-NH2

917435

BocA1V1PF2-OPEG1-NH2 hydrochloride, ≥95%

916978

BocA1V2PF1, ≥95%

917699

BocA1V2PF2-NHC10-NH2, ≥85%

917222

A1V2PF1-NHEt, ≥95%

917958

BocA1V2PF2-NHPEG1-NH2

916714

A1V2PF2-NHEt, ≥95%

917192

A1V2PF2-NHEt-PEG3-NH2, ≥95%

916935

A1V2PF2-NHEt-PEG1-NH2

917443

BocA1V2PF2-NHC6-NH2

919381

CCW16, ≥95%

CIX001

ComInnex IAP Ligand Library

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mikihiko Naito et al.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein
Nobumichi Ohoka et al.
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies
Tasuku Ishida et al.
SLAS discovery : advancing life sciences R & D, 26(4), 484-502 (2020-11-05)
Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to

Articles

Degrader Building Blocks with IAP In Silico-Derived Ligands

Targeted protein degradation reduces disease-relevant proteins in cells using small molecules, hijacking endogenous proteolysis systems.

Degrader Building Blocks with IAP In Silico-Derived Ligands

Targeted protein degradation reduces disease-relevant proteins in cells using small molecules, hijacking endogenous proteolysis systems.

Degrader Building Blocks with IAP In Silico-Derived Ligands

Targeted protein degradation reduces disease-relevant proteins in cells using small molecules, hijacking endogenous proteolysis systems.

Degrader Building Blocks with IAP In Silico-Derived Ligands

Targeted protein degradation reduces disease-relevant proteins in cells using small molecules, hijacking endogenous proteolysis systems.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service